Table 1.
Characteristics of the study cohort, training set, and validation set. Training and validation set data included only patients successfully analyzed by the systems pathology platform.
| Entire cohort | Training | Validation | |
|---|---|---|---|
| Number of patients | 881 | 345 | 319 |
| Follow-up from prostatectomy (years) | |||
| Median | 6.1 | 6.4 | 6.6 |
| IQR | 4.6, 8.0 | 4.8, 8.5 | 5.3, 8.7 |
| Age (years) | |||
| Mean (SD) | 60.8 (6.6) | 61.0 (6.6) | 60.5 (6.7) |
| Pre-operative PSA (ng/dl) | |||
| < 4.0 | 72 (8%) | 22 (6%) | 31 (10%) |
| 4.0 – 9.9 | 495 (56%) | 193 (56%) | 163 (51%) |
| 10.0 – 20.0 | 222 (25%) | 90 (26%) | 87 (27%) |
| > 20.0 | 92 (11%) | 40 (12%) | 38 (12%) |
| Clinical Stage | |||
| T1 | 439 (50%) | 176 (51%) | 152 (48%) |
| T2 | 427 (48%) | 160 (46%) | 162 (51%) |
| T3 | 15 (2%) | 9 (3%) | 5 (1%) |
| Biopsy Gleason Score | |||
| ≤ 6 | 564 (64%) | 224 (65%) | 199 (62%) |
| 7 | 256 (29%) | 93 (27%) | 97 (31%) |
| ≥ 8 | 61 (7%) | 28 (8%) | 23 (7%) |
| Pathologic Gleason Score | |||
| ≤ 6 | 316 (36%) | 128 (37%) | 118 (37%) |
| 7 | 478 (54%) | 182 (53%) | 167 (52%) |
| ≥ 8 | 87 (10%) | 35 (10%) | 34 (11%) |
| Surgical Margins | |||
| Positive | 305 (35%) | 117 (34%) | 120 (38%) |
| Negative | 576 (65%) | 228 (66%) | 199 (62%) |
| Extracapsular Extension | |||
| Yes | 262 (30%) | 103 (30%) | 97 (30%) |
| No | 619 (70%) | 242 (70%) | 222 (70%) |
| Seminal Vesicle Involvement | |||
| Yes | 79 (9%) | 29 (8%) | 28 (9%) |
| No | 802 (91%) | 316 (92%) | 291 (91%) |
| Lymph Node Involvement | |||
| Yes | 27 (3%) | 13 (4%) | 11 (3%) |
| No | 854 (97%) | 332 (96%) | 308 (97%) |
| Biochemical Recurrence (PSA > 0.2 ng/ml) | |||
| Yes | 214 (24%) | 87 (25%) | 79 (25%) |
| No | 667 (76%) | 258 (75%) | 240 (75%) |
| Clinical Failure* | |||
| Yes | 81 (9%) | 30 (9%) | 27 (8%) |
| No | 800 (91%) | 315 (91%) | 292 (92%) |
*
Metastases, rising PSA in castrate state, or death from prostate cancer